{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Arozarena I"],"funding":["Cancer Research UK"],"pagination":["154"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4079649"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["<h4>Background</h4>The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent. In melanoma, the existence of a BRAF mutation is a main predictor for successful BRAF-targeted therapy. However, despite initial successes with these therapies, patients relapse within a year and have to move on to other therapies. Moreover, patients harbouring a wild type BRAF gene (including 25% with NRAS mutations) still require alternative treatment such as chemotherapy. Multiple genetic parameters have been associated with response to chemotherapy, but despite their high frequency in melanoma nothing is known about the impact of BRAF or NRAS mutations on the response to chemotherapeutic agents.<h4>Methods</h4>Using cell proliferat"],"journal":["Molecular cancer"],"pubmed_title":["Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells."],"pmcid":["PMC4079649"],"funding_grant_id":["C11591/A10202","16416"],"pubmed_authors":["Erice O","Goicoechea I","Ferguson J","Wellbrock C","Arozarena I","Margison GP"],"additional_accession":[]},"is_claimable":false,"name":"Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.","description":"<h4>Background</h4>The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent. In melanoma, the existence of a BRAF mutation is a main predictor for successful BRAF-targeted therapy. However, despite initial successes with these therapies, patients relapse within a year and have to move on to other therapies. Moreover, patients harbouring a wild type BRAF gene (including 25% with NRAS mutations) still require alternative treatment such as chemotherapy. Multiple genetic parameters have been associated with response to chemotherapy, but despite their high frequency in melanoma nothing is known about the impact of BRAF or NRAS mutations on the response to chemotherapeutic agents.<h4>Methods</h4>Using cell proliferat","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Jun","modification":"2025-04-26T08:32:23.628Z","creation":"2019-03-27T01:31:18Z"},"accession":"S-EPMC4079649","cross_references":{"pubmed":["24941944"],"doi":["10.1186/1476-4598-13-154"]}}